Hot Spotlight

The small-molecule CXCR4 antagonist Mavorixafor is used for the treatment of WHIM syndrome and chronic neutropenia

9 April 2024
4 min read

Chemokines constitute a large family, primarily composed of small secreted cytokine proteins, that coordinate the migration of white blood cells by interacting with members of the GPCR (G protein-coupled receptor) family on the cell membrane. Chemokines mediate normal host defense and tissue repair but can also support pathological immune responses, including chronic inflammation, autoimmunity, and cancer. The chemokine system is also a primary target for pathogens, such as the Human Immunodeficiency Virus (HIV) and Plasmodium vivax, to evade or exploit the immune system. An increasing number of studies recognize chemokines' additional immune and non-immune functions. Non-immune functions may be advantageous for embryonic development but also detrimental in cancer. 

doi.org/10.3389/fimmu.2019.00379

CXCR4 (C-X-C chemokine receptor type 4) is a chemokine receptor belonging to the G protein-coupled receptor family. It plays a pivotal role in regulating the immune system, inflammatory responses, and hematopoietic processes. CXCR4 primarily binds its endogenous ligand CXCL12, participating in a variety of physiological and pathological processes. Clinically, the CXCR4 receptor has become a hot topic of research, as it plays important roles in a multitude of diseases, including cancer metastasis, hematopoietic stem cell transplantation, cardiovascular diseases, and immune disorders.

WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis) is a rare genetic immune disorder characterized by aberrant over-signaling of the CXCR4/CXCL12 pathway, resulting in impaired mobilization and migration of leukocytes in the bone marrow. The acronym of the syndrome reflects its primary features, including warts (warts), hypogammaglobulinemia (hypogammaglobulinemia), recurrent infections (infections), and bone marrow retention (myelokathexis).

图形用户界面, 文本, 应用程序

描述已自动生成
https://investors.x4pharma.com/

Patients with WHIM syndrome have very low levels of neutrophils (neutropenia) and lymphocytes (lymphopenia) in their blood, making them prone to recurrent infections, at a higher risk for pulmonary diseases, and complications from persistent human papillomavirus (HPV) infections, such as refractory condyloma acuminatum. Additionally, these individuals may experience limited antibody production due to low gammaglobulin levels and have an increased risk of developing certain types of cancer.

In December 2023, X4 Pharmaceuticals issued an announcement stating that its ongoing Phase 2 clinical trial had achieved some initial data. The trial was evaluating the safety and efficacy of once-daily oral mavorixafor in combination with or without the concurrent use of injectable Granulocyte Colony-Stimulating Factor (G-CSF) in patients with idiopathic, cyclic, or congenital neutropenia.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

In October 2023, the company announced that the U.S. FDA had accepted for priority review the New Drug Application (NDA) for mavorixafor for the treatment of WHIM syndrome in patients aged 12 and older. The FDA granted priority review status to the mavorixafor NDA, committing to completing the review within six months from the date of acceptance, and set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to statistics from the Synapse database, to date, there are two therapeutic drugs globally targeting CXCR4 that have been approved. These are the small-molecule antagonist Plerixafor by Sanofi and the peptide antagonist Motixafortide.

图表

中度可信度描述已自动生成

Mavorixafor is an orally administered small-molecule antagonist targeting the CXCR4 receptor, originally developed by Genzyme Corp., a subsidiary of Sanofi. In 2010, the company published its first research paper on mavorixafor (AMD070, AMD10070) in the Journal of Medicinal Chemistry.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Based on the structure-activity relationship data of existing molecules, researchers, through lead optimization, discovered AMD070: a potent and selective CXCR4 antagonist with an IC(50) value of 13 nM in CXCR4 125I-SDF binding inhibition assays. The compound can inhibit the replication of T-tropic HIV-1 (strain NL4.3) in both MT-4 cells and PBMCs, with IC(50) values of 2 nM and 26 nM, respectively, and remains non-toxic to cells at concentrations exceeding 23 µM. This compound is the first small-molecule, orally bioavailable CXCR4 antagonist developed for the treatment of HIV-1 infection.

图示

描述已自动生成

In the subsequent clinical data released, it was demonstrated that AMD10070 has certain antiviral activity against tropical HIV-1, with good tolerability and no serious safety concerns. However, due to histological changes observed in the liver tissue in long-term animal studies, AMD11070 is currently on clinical hold; further preclinical safety evaluations are underway.

图形用户界面, 文本, 应用程序

描述已自动生成

In 2017, X4 Pharmaceuticals raised $27 million to advance the CXCR4 inhibitor mavorixafor, which was acquired from Sanofi. According to the latest materials updated by X4 Pharmaceuticals, the company is now conducting trials for the use of mavorixafor in treating WHIM syndrome and chronic neutropenia.

图片包含 日程表

描述已自动生成

The 4WHIM trial achieved its primary endpoints, namely the duration of absolute neutrophil counts (ANC) exceeding thresholds and certain key clinical efficacy assessments.

Compared to placebo, mavorixafor significantly reduced the time with ANC above the critical threshold within 52 weeks, with an average TATANC (Time Above Threshold Absolute Neutrophil Count) of 15.04 hours longer than the 2.75 hours in the placebo group.

图表

描述已自动生成

The longer mavorixafor was used, the greater the reduction in infection rates.

图表, 瀑布图

描述已自动生成

表格

描述已自动生成

图形用户界面, 文本, 应用程序

描述已自动生成

Werewolf Therapeutics Unveils Promising Results of WTX-518 and WTX-712 in Cancer Treatment Trial
Latest Hotspot
3 min read
Werewolf Therapeutics Unveils Promising Results of WTX-518 and WTX-712 in Cancer Treatment Trial
9 April 2024
Werewolf Therapeutics Reveals Early Stage Study Outcomes Highlighting the Cancer-Fighting Capabilities of Immune-Stimulating Drugs WTX-518 and WTX-712.
Read →
Pharvaris is developing a bradykinin B2 receptor antagonist for the treatment of hereditary angioedema
Hot Spotlight
4 min read
Pharvaris is developing a bradykinin B2 receptor antagonist for the treatment of hereditary angioedema
9 April 2024
Deucrictibant is a new, potent oral small-molecule bradykinin B2 receptor antagonist, originally developed by the Pharvaris team.
Read →
Promising Results for BTX-A51 in Liposarcoma Models: Edgewood Oncology's Trial Findings
Latest Hotspot
3 min read
Promising Results for BTX-A51 in Liposarcoma Models: Edgewood Oncology's Trial Findings
8 April 2024
Edgewood Oncology reveals encouraging outcomes from a research-driven trial for BTX-A51 in early tests on liposarcoma models.
Read →
What is Immunosuppressant?
"What" Series
2 min read
What is Immunosuppressant?
8 April 2024
An immunosuppressant is a type of medication that suppresses or reduces the strength of the immune system.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.